GlassScriptPhysician profile
Musa Ajala
NPI 1902889942
$1,290.65
in general payments reported to CMS, 2019-2025
14 companies · $143 in 2025
The $143 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.98 · 2021: $480 · 2022: $260 · 2023: $134 · 2024: $259 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510 · Education: $26.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.84 |
| Education | $26.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $390.60 | 2021-2023 | Korsuva, Veltassa |
| Travere Therapeutics, INC. | $214.08 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.20 | 2022-2024 | |
| Akebia Therapeutics INC | $121.47 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $81.43 | 2024-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $81.31 | 2021-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $67.53 | 2023-2024 | Jynarque |
| Opko Pharmaceuticals, LLC | $38.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.82 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $30.22 | 2025 | Tarpeyo |
| Gilead Sciences, INC. | $25.42 | 2021 | |
| Amgen INC. | $24.18 | 2024 | Krystexxa |
| Fresenius USA Marketing, INC. | $21.60 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Musa Ajala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.